ETF Holdings Breakdown of INSM

INSM institutional holdings

The adjusted close for INSM on 2025-11-11 was 193.69

The following institutional investment holdings of INSM have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	134,027	USD 25,959,690 0.9%	193.69
2025-11-11	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	72,265	USD 13,997,008 0.9%	193.69
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	136,990	USD 26,533,593 0.9%	193.69
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	136,990	USD 26,533,593 0.9%	193.69
2025-11-11	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	2,633	USD 509,986 0.9%	193.69
2025-11-11	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	3,415 6.3%	USD 661,451 7.1%	193.69
2025-11-11	IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF)	93	USD 18,013 0.9%	193.69
2025-11-11	IE000WHL2ZK1 (iShares U.S. Equity High Income UCITS ETF USD Inc)	83 25.3%	USD 16,076 26.0%	193.69
2025-11-11	IE0009VWHAE6 (iShares US Equity Enhanced Active UCITS ETF USD (Acc))	5,684	USD 1,100,934 0.9%	193.69
Total =		492,180	USD 95,330,344

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with INSM

Analysts Set Insmed, Inc. (NASDAQ:INSM) Price Target at $139.86

Insmed, Inc. (NASDAQ:INSM – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seventeen brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 1-year target price among brokerages […] - 2025-09-17 02:58:45

Insmed (NASDAQ:INSM) Reaches New 12-Month High on Analyst Upgrade

Shares of Insmed, Inc. (NASDAQ:INSM – Get Free Report) hit a new 52-week high on Monday after Guggenheim raised their price target on the stock from $125.00 to $172.00. Guggenheim currently has a buy rating on the stock. Insmed traded as high as $146.91 and last traded at $145.86, with a volume of 288114 shares […] - 2025-09-10 02:26:50

Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11

Insmed (NASDAQ:INSM) Earns Outperform Rating from Analysts at William Blair

Stock analysts at William Blair initiated coverage on shares of Insmed (NASDAQ:INSM – Get Free Report) in a research note issued on Wednesday, MarketBeat Ratings reports. The firm set an “outperform” rating on the biopharmaceutical company’s stock. Other research analysts also recently issued reports about the stock. Truist Financial upped their target price on shares […] - 2025-08-22 02:54:45

The Goldman Sachs Group Forecasts Strong Price Appreciation for Insmed (NASDAQ:INSM) Stock

Insmed (NASDAQ:INSM – Get Free Report) had its target price increased by equities researchers at The Goldman Sachs Group from $114.00 to $142.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target indicates a potential upside […] - 2025-08-15 07:10:57

INSM Crosses Above Average Analyst Target

In recent trading, shares of Insmed Inc (Symbol: INSM) have crossed above the average analyst 12-month target price of $119.12, changing hands for $122.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuati - 2025-08-13 10:41:52

Insmed (NASDAQ:INSM) Reaches New 1-Year High Following Analyst Upgrade

Insmed, Inc. (NASDAQ:INSM – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Monday after Wells Fargo & Company raised their price target on the stock from $119.00 to $130.00. Wells Fargo & Company currently has an overweight rating on the stock. Insmed traded as high as $113.41 and last […] - 2025-08-13 02:23:00

XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54

Insmed, Inc. (NASDAQ:INSM) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its stake in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 3.6% during the 1st quarter, Holdings Channel reports. The institutional investor owned 1,602,655 shares of the biopharmaceutical company’s stock after buying an additional 56,048 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Insmed were […] - 2025-08-12 05:59:02

Mackenzie Financial Corp Acquires 2,220 Shares of Insmed, Inc. (NASDAQ:INSM)

Mackenzie Financial Corp lifted its holdings in Insmed, Inc. (NASDAQ:INSM – Free Report) by 20.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,103 shares of the biopharmaceutical company’s stock after buying an additional 2,220 shares during the quarter. Mackenzie Financial Corp’s holdings in […] - 2025-08-06 05:07:44

Insmed, Inc. (NASDAQ:INSM) Shares Acquired by Cwm LLC

Cwm LLC grew its holdings in Insmed, Inc. (NASDAQ:INSM – Free Report) by 24.5% in the 1st quarter, HoldingsChannel.com reports. The fund owned 2,052 shares of the biopharmaceutical company’s stock after buying an additional 404 shares during the quarter. Cwm LLC’s holdings in Insmed were worth $157,000 as of its most recent SEC filing. Several […] - 2025-07-29 04:28:55

Allianz Asset Management GmbH Has $5.74 Million Holdings in Insmed, Inc. (NASDAQ:INSM)

Allianz Asset Management GmbH raised its stake in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 4.9% in the first quarter, Holdings Channel.com reports. The firm owned 75,284 shares of the biopharmaceutical company’s stock after buying an additional 3,534 shares during the period. Allianz Asset Management GmbH’s holdings in Insmed were worth $5,743,000 as […] - 2025-07-28 05:46:50

Insmed, Inc. (NASDAQ:INSM) Shares Bought by Xponance Inc.

Xponance Inc. boosted its stake in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 5.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 13,359 shares of the biopharmaceutical company’s stock after buying an additional 670 shares during the period. Xponance Inc.’s holdings in Insmed […] - 2025-07-17 06:35:03

Envestnet Asset Management Inc. Grows Holdings in Insmed, Inc. (NASDAQ:INSM)

Envestnet Asset Management Inc. raised its position in Insmed, Inc. (NASDAQ:INSM – Free Report) by 26.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 325,307 shares of the biopharmaceutical company’s stock after purchasing an additional 68,949 shares during the quarter. Envestnet Asset Management […] - 2025-07-16 07:23:19

Sara Bonstein Sells 57,764 Shares of Insmed, Inc. (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM – Get Free Report) CFO Sara Bonstein sold 57,764 shares of the company’s stock in a transaction on Monday, July 7th. The shares were sold at an average price of $95.86, for a total value of $5,537,257.04. Following the completion of the sale, the chief financial officer owned 84,017 shares in the […] - 2025-07-11 05:13:00

Teacher Retirement System of Texas Sells 2,654 Shares of Insmed, Inc. (NASDAQ:INSM)

Teacher Retirement System of Texas lessened its holdings in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 5.5% during the 1st quarter, Holdings Channel.com reports. The firm owned 45,683 shares of the biopharmaceutical company’s stock after selling 2,654 shares during the period. Teacher Retirement System of Texas’ holdings in Insmed were worth $3,485,000 at […] - 2025-07-09 05:48:57

Brokerages Set Insmed, Inc. (NASDAQ:INSM) Target Price at $106.80

Shares of Insmed, Inc. (NASDAQ:INSM – Get Free Report) have earned an average rating of “Buy” from the seventeen brokerages that are presently covering the stock, MarketBeat Ratings reports. Seventeen equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have updated their coverage on the […] - 2025-07-04 02:40:47

Insmed, Inc. (NASDAQ:INSM) CFO Sara Bonstein Sells 57,765 Shares

Insmed, Inc. (NASDAQ:INSM – Get Free Report) CFO Sara Bonstein sold 57,765 shares of the stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $101.78, for a total value of $5,879,321.70. Following the completion of the sale, the chief financial officer now owns 93,536 shares in the […] - 2025-06-27 05:06:55

Avior Wealth Management LLC Raises Holdings in Insmed, Inc. (NASDAQ:INSM)

Avior Wealth Management LLC lifted its holdings in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 82.2% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 4,151 shares of the biopharmaceutical company’s stock after acquiring an additional 1,873 shares during the period. Avior Wealth Management LLC’s holdings […] - 2025-06-23 05:12:58

Is Insmed Stock Overvalued at $98?

Insmed Inc (NASDAQ: INSM) was nothing short of a juggernaut last month, skyrocketing 45%, while the S&P500 index gained 3% during the same period. What’s fueling the fire? Insmed announced that its Phase IIb trial for treprostinil palmitil inhalation powder (TPIP) in pulmonar - 2025-06-17 03:35:22

Notable ETF Outflow Detected - IWO, SFM, INSM, FTAI

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 2000 Growth ETF (Symbol: IWO) where we have detected an approximate $123.7 million dollar outflow -- that's a 1.1% decrease week ove - 2025-06-16 11:49:52

Insmed Incorporated (NASDAQ:INSM) CFO Sells $5,148,105.92 in Stock

Insmed Incorporated (NASDAQ:INSM – Get Free Report) CFO Sara Bonstein sold 57,766 shares of the company’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $89.12, for a total transaction of $5,148,105.92. Following the sale, the chief financial officer now directly owns 103,412 shares in the company, […] - 2025-06-16 05:18:57

Park Avenue Securities LLC Has $842,000 Holdings in Insmed Incorporated (NASDAQ:INSM)

Park Avenue Securities LLC boosted its position in shares of Insmed Incorporated (NASDAQ:INSM – Free Report) by 38.7% during the 1st quarter, Holdings Channel reports. The institutional investor owned 11,036 shares of the biopharmaceutical company’s stock after purchasing an additional 3,081 shares during the quarter. Park Avenue Securities LLC’s holdings in Insmed were worth $842,000 […] - 2025-06-13 05:18:50

Morgan Stanley Increases Insmed (NASDAQ:INSM) Price Target to $102.00

Insmed (NASDAQ:INSM – Get Free Report) had its price objective lifted by stock analysts at Morgan Stanley from $90.00 to $102.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price suggests a potential upside of 5.28% from the stock’s previous close. […] - 2025-06-13 04:40:52

Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Royal Bank of Canada Analyst Says

Insmed (NASDAQ:INSM – Get Free Report) had its target price raised by research analysts at Royal Bank of Canada from $99.00 to $106.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target would suggest a potential upside of 9.41% […] - 2025-06-13 04:40:51

Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Mizuho Analyst Says

Insmed (NASDAQ:INSM – Get Free Report) had its price objective lifted by equities research analysts at Mizuho from $96.00 to $110.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Mizuho’s price target points to a potential upside of 13.54% from the company’s current price. […] - 2025-06-13 04:40:49

Insmed (NASDAQ:INSM) Shares Up 4.5% Following Analyst Upgrade

Insmed Incorporated (NASDAQ:INSM – Get Free Report)’s stock price traded up 4.5% during trading on Wednesday after The Goldman Sachs Group raised their price target on the stock from $100.00 to $112.00. The Goldman Sachs Group currently has a buy rating on the stock. Insmed traded as high as $93.82 and last traded at $95.02. […] - 2025-06-13 02:17:01

INSM Crosses Above Average Analyst Target

In recent trading, shares of Insmed Inc (Symbol: INSM) have crossed above the average analyst 12-month target price of $97.70, changing hands for $97.98/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation - 2025-06-12 08:33:46

Bank of America Increases Insmed (NASDAQ:INSM) Price Target to $109.00

Insmed (NASDAQ:INSM – Free Report) had its price objective boosted by Bank of America from $94.00 to $109.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently commented on INSM. Stifel Nicolaus reduced their target price […] - 2025-06-12 05:08:53

Wells Fargo & Company Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price

Insmed (NASDAQ:INSM – Free Report) had its target price upped by Wells Fargo & Company from $107.00 to $119.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. A number of other research firms also recently weighed in on INSM. Stifel Nicolaus decreased […] - 2025-06-12 04:32:54

Back to Listing

Disclaimer